NASDAQ:REGNRegeneron Pharmaceuticals Stock Price, Forecast & News

Regeneron Pharmaceuticals' stock was trading at $464.70 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, REGN stock has increased by 28.9% and is now trading at $598.86.
View which stocks have been most impacted by Coronavirus.

27 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 11 hold ratings, 15 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) released its earnings results on Wednesday, August, 5th. The biopharmaceutical company reported $7.16 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $5.59 by $1.57. The biopharmaceutical company had revenue of $1.95 billion for the quarter, compared to the consensus estimate of $1.74 billion. Regeneron Pharmaceuticals had a net margin of 37.30% and a return on equity of 26.71%. The business's revenue was up 23.7% on a year-over-year basis. During the same quarter last year, the company posted $6.02 earnings per share.
View Regeneron Pharmaceuticals' earnings history.

Regeneron Pharmaceuticals announced that its Board of Directors has approved a share buyback plan on Tuesday, November 5th 2019, which permits the company to buyback $1,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to purchase up to 2.9% of its stock through open market purchases. Stock buyback plans are usually an indication that the company's board believes its stock is undervalued.

27 Wall Street analysts have issued 1-year target prices for Regeneron Pharmaceuticals' shares. Their forecasts range from $325.00 to $800.00. On average, they anticipate Regeneron Pharmaceuticals' share price to reach $592.78 in the next year. This suggests that the stock has a possible downside of 1.0%.
View analysts' price targets for Regeneron Pharmaceuticals.

Media coverage about REGN stock has trended somewhat positive on Wednesday, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Regeneron Pharmaceuticals earned a daily sentiment score of 1.0 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days.
View the latest news about Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals saw a decrease in short interest in the month of July. As of July 31st, there was short interest totaling 1,990,000 shares, a decrease of 6.1% from the July 15th total of 2,120,000 shares. Based on an average daily volume of 1,310,000 shares, the days-to-cover ratio is currently 1.5 days. Approximately 1.9% of the company's stock are sold short.
View Regeneron Pharmaceuticals' Short Interest.

Some companies that are related to Regeneron Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU), Novavax (NVAX) and Repligen (RGEN).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Johnson & Johnson (JNJ), Micron Technology (MU), Walt Disney (DIS), Visa (V) and salesforce.com (CRM).

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Regeneron Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (0.44%), Swiss National Bank (0.44%), First Trust Advisors LP (0.33%), LSV Asset Management (0.29%), Candriam Luxembourg S.C.A. (0.21%) and New York State Common Retirement Fund (0.19%). Company insiders that own Regeneron Pharmaceuticals stock include Andrew J Murphy, Arthur F Ryan, Bonnie L Bassler, Christopher R Fenimore, George L Sing, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Leonard S Schleifer, Michael S Brown, Neil Stahl, P Roy Vagelos, Robert E Landry and Sanofi.
View institutional ownership trends for Regeneron Pharmaceuticals.

REGN stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., LSV Asset Management, Toronto Dominion Bank, Bank of Nova Scotia, NN Investment Partners Holdings N.V., NN Investment Partners Holdings N.V., Cannell Peter B & Co. Inc., and Natixis Advisors L.P.. Company insiders that have sold Regeneron Pharmaceuticals company stock in the last year include Andrew J Murphy, Arthur F Ryan, Bonnie L Bassler, Christopher R Fenimore, George L Sing, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Leonard S Schleifer, Michael S Brown, Neil Stahl, P Roy Vagelos, Robert E Landry, and Sanofi.
View insider buying and selling activity for Regeneron Pharmaceuticals.

REGN stock was purchased by a variety of institutional investors in the last quarter, including Swiss National Bank, Robeco Institutional Asset Management B.V., First Trust Advisors LP, Sumitomo Mitsui Trust Holdings Inc., Mn Services Vermogensbeheer B.V., PGGM Investments, Monashee Investment Management LLC, and Principal Financial Group Inc..
View insider buying and selling activity for Regeneron Pharmaceuticals.

Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of REGN stock can currently be purchased for approximately $598.86.

Regeneron Pharmaceuticals has a market capitalization of $65.89 billion and generates $7.86 billion in revenue each year. The biopharmaceutical company earns $2.12 billion in net income (profit) each year or $21.47 on an earnings per share basis. Regeneron Pharmaceuticals employs 8,100 workers across the globe.

The official website for Regeneron Pharmaceuticals is www.regeneron.com.

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at 914-847-7000 or via email at [email protected]